← LIGAND PHARMACEUTICALS INC
| Annual Trend | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $109.0m |
$141.1m
+29.48%
|
$251.5m
+78.21%
|
$120.3m
-52.17%
|
$186.4m
+54.98%
|
$277.1m
+48.66%
|
$196.2m
-29.19%
|
$131.3m
-33.09%
|
$167.1m
+27.28%
|
$268.1m
+60.40%
|
$290.5m
+8.38%
|
|
| Cost of Revenue | $5.6m |
$5.4m
-3.68%
|
$6.3m
+18.10%
|
($728.7m)
-11598.78%
|
$96.1m
+113.19%
|
$140.8m
+46.41%
|
$123.1m
-12.51%
|
$66.6m
-45.93%
|
$111.1m
+66.84%
|
$134.6m
+21.20%
|
$13.3m
-90.14%
|
|
| Gross Profit (Calculated) (derived) | $103.4m |
$135.7m
+31.27%
|
$245.1m
+80.58%
|
($608.4m)
-348.21%
|
$90.3m
+114.84%
|
$136.4m
+51.06%
|
$73.1m
-46.40%
|
$64.7m
-11.45%
|
$56.0m
-13.42%
|
$133.5m
+138.10%
|
— | |
| Interest Income (Expense), Net | ($12.2m) |
($11.4m)
+6.39%
|
— | — | — | — | — | — | — | — | $24.2m | |
| Research and Development Expense | $21.2m | $26.9m | $27.9m | $55.9m | $59.4m | $69.0m | $36.1m | $24.5m | $21.4m | $81.2m | $41.3m | |
| General and Administrative Expense | $26.6m | $28.7m | $37.7m | $41.9m | $64.4m | $57.5m | $70.1m | $52.8m | $78.7m | $92.4m | $103.4m | |
| Amortization of Intangible Assets | $10.6m | $11.3m | $15.8m | $16.9m | $23.4m | $47.2m | — | — | — | — | — | |
| Operating Lease, Expense | — | — | — | $2.1m | $2.1m | $2.6m | $700k | $1.4m | $1.3m | $900k | — | |
| Operating expenses: | ||||||||||||
| Operating Costs and Expenses | $65.1m | $73.0m | $87.7m | $126.0m | $177.7m | $198.2m | $193.2m | $121.5m | $189.7m | $227.1m | — | |
| Operating Income (Loss) | $43.9m |
$68.1m
+55.12%
|
$163.7m
+140.51%
|
$807.1m
+392.94%
|
$25.8m
-96.80%
|
$78.9m
+205.26%
|
$3.0m
-96.15%
|
$11.9m
+293.22%
|
($22.6m)
-289.30%
|
$41.0m
+281.38%
|
$100.1m
+144.13%
|
|
| Other Operating Income (Expense), Net | $43.9m | $68.1m | $163.7m | $807.1m | $25.8m | $78.9m | $0 | $0 | $22.6m | $41.0m | $100.1m | |
| Gain (Loss) on Investments | — | — | — | $2.9m | ($16.9m) | ($4.0m) | $28.5m | $46.4m | $75.0m | $18.4m | — | |
| Other Nonoperating Income (Expense) | $2.7m | $5.2m | ($6.3m) | ($6.0m) | ($108k) | ($8.9m) | $4.2m | ($2.0m) | ($54.9m) | ($89k) | — | |
| Interest Expense (non-operating) | $12.8m | $13.5m | $48.3m | $35.7m | $27.4m | $19.6m | $1.8m | $656k | $3.0m | $4.7m | $6.2m | |
| Income (Loss) from Equity Method Investments | ($23.1m) | ($2.0m) | $42.3m | $2.9m | — | — | — | ($1.8m) | ($12.8m) | $0 | — | |
| Income (Loss) from Continuing Operations before Income Taxes, Domestic | $43.9m | $68.1m | $163.7m | $807.1m | $25.8m | $78.9m | $3.0m | $11.9m | $22.6m | $126.4m | $238.0m | |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest | $43.9m | $68.1m | $163.7m | — | $25.8m | $47.3m | $36.0m | $63.7m | $2.5m | $159.0m | $238.0m | |
| Current Income Tax Expense (Benefit) | $33k | $372k | $266k | $92.5m | $11.5m | ($1.2m) | $10.7m | ($188k) | $22.4m | $12.6m | $40.7m | |
| Income Tax Expense (Benefit) | $10.3m | $44.7m | $30.0m | $167.3m | ($7.6m) | ($9.8m) | $41.2m | $9.8m | $6.5m | $34.5m | $40.7m | |
| Net Income (Loss) Attributable to Parent | ($1.6m) |
$12.6m
+867.48%
|
$143.3m
+1041.45%
|
$629.3m
+339.09%
|
($3.0m)
-100.47%
|
$57.1m
+2014.17%
|
($33.4m)
-158.39%
|
$52.2m
+256.33%
|
($4.0m)
-107.73%
|
$124.5m
+3186.63%
|
$197.2m
+58.47%
|
|
| Net Income (Loss) Attributable to Noncontrolling Interest | $0 | $0 | — | — | — | — | — | — | — | — | $197.2m | |
| Earnings Per Share, Basic | ($0.08) | $0.60 | $6.77 | $33.13 | ($0.18) | $3.44 | ($1.98) | $3.02 | ($0.22) | $6.44 | $10.15 | |
| Earnings Per Share, Diluted | ($0.08) | $0.53 | $5.96 | $31.85 | ($0.18) | $3.31 | ($1.98) | $2.94 | ($0.22) | $6.13 | $9.71 | |
| Income (Loss) from Continuing Operations, Per Basic Share | ($0) | $1 | $7 | — | $0 | $5 | ($0) | $3 | ($0) | $6 | — | |
| Income (Loss) from Continuing Operations, Per Diluted Share | ($0) | $1 | $6 | — | $0 | $4 | ($0) | $3 | ($0) | $6 | — | |
| Weighted Average Number of Shares Outstanding, Basic | 20.8m | 21.0m | 21.2m | 19.0m | 16.2m | 16.6m | 16.9m | 17.3m | 18.3m | 19.3m | 19.7m | |
| Weighted Average Number of Shares Outstanding, Diluted | 20.8m | 23.5m | 24.1m | 19.8m | 16.2m | 17.2m | 16.9m | 17.8m | 18.3m | 20.3m | 21.4m | |
| Additional Financial Items | ||||||||||||
| Goodwill, Impairment Loss | $0 | — | — | — | — | — | — | — | — | — | $30.6m | |
| Realized Investment Gains (Losses) | $2.4m | $831k | $2.6m | $41k | — | — | — | — | — | — | — | |
| Discontinued Operation, Income (Loss) from Discontinued Operation During Phase-out Period, Net of Tax | $731k | $0 | $0 | — | — | — | — | — | — | — | — | |
| Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent | $43.9m | $68.1m | $163.7m | — | $25.8m | $78.9m | ($5.2m) | $53.8m | ($4.0m) | $124.5m | — | |
| Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest | ($2.4m) | $12.6m | $143.3m | — | $25.8m | $78.9m | $3.0m | $11.9m | $22.6m | $41.0m | — | |
| Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent | $43.9m | $68.1m | $163.7m | $807.1m | $25.8m | $78.9m | ($28.1m) | ($1.7m) | $22.6m | $41.0m | — |